This webinar has applied to CAMPEP for 1 MPCEC hour and has been approved by ASRT for 1 Category A continuing education credit.
Surgery remains the cornerstone for the management of thymoma. Complete surgical resection is recognized as the constant and significant factor for prognosis. However, in locally advanced thymomas, achieving R0 resection remains challenging due to local-regional invasion of the disease. Induction treatment, with the aim of reducing bulky tumor mass, offers a new strategy to facilitate total surgical resection.
During this webinar, Prof. Du will review recent progress and provide a comprehensive overview of the induction strategy in locally advanced thymoma using the TomoTherapy® System.
Shisuo Du, M.D., Ph.D., Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
Professor Shisuo Du is the Deputy Director of the Department of Radiotherapy at Zhongshan Hospital Affiliated with Fudan University.
In 2010, he received his Ph.D. degree in radiation oncology from Fudan University. From 2011 to 2015, he worked as a postdoctoral fellow in the Department of Radiotherapy, Cancer Center, New York University. From 2015 to 2018, he was an associate professor in the Department of Radiotherapy, at Thomas Jefferson University, USA.
Prof. Du is a member of ASTRO, AACR and CSTRO. He has published more than 40 SCI papers, presided over 3 projects of the National Natural Science Foundation of China, 1 project of the Shanghai Natural Science Foundation and participated in the application of 6 NIH or NCI projects. He participated in the compilation of 2 books, won second place for the Chinese Medical Award, and was a reviewer for the National Natural Science Foundation of China.
Moderator: Umberto Ricardi, M.D., University of Turin, Italy
Professor Umberto Ricardi is currently Full Professor and Chairman of Radiation Oncology at University of Turin, Italy. He is Dean of School of Medicine at University of Turin. Prof. Ricardi is also serving as Director of the Department of Oncology at Health and Science Academic Hospital in Turin.
Prof. Ricardi’s main areas of clinical and scientific interest include lymphoma, lung cancer and CNS tumors. He is also an expert in the development of cutting-edge technologies in Radiation Oncology. Prof. Ricardi has authored more than 360 full research papers and participated as invited speaker in a number of national and international conferences. He is active in many educational activities, both at national and international level.
Prof. Ricardi is member of numerous national and international scientific societies. He is member of the Steering Committee of ILROG (International Lymphoma Radiation Oncology Group). Prof. Ricardi is the former ESTRO (European SocieTy for Radiotherapy and Oncology) President, serving as President between April 2018-April 2020.